United Laboratories International Holdings Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de United Laboratories International Holdings de 3.9% y 6.1% por año respectivamente. Se prevé que el BPA crezca en un 4% al año. Se espera que la rentabilidad financiera sea de 19.5% en 3 años.

Información clave

3.9%

Tasa de crecimiento de los beneficios

4.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	11.2%
Tasa de crecimiento de los ingresos	6.1%
Rentabilidad financiera futura	19.5%
Cobertura de analistas	Good
Última actualización	31 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

Nov 11

The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market

Oct 23

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

Aug 30

Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified

Feb 29

The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement

Jan 04

United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt

Dec 14

With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case

Nov 26

Is United Laboratories International Holdings (HKG:3933) A Risky Investment?

Aug 31

Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?

Aug 10

United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet

Dec 23

Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?

Oct 19

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

Aug 30

Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?

Mar 08

The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It

Feb 18

The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 03

Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?

Jan 19

We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide

Jan 04

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

Dec 20

What Type Of Shareholders Own The Most Number of The United Laboratories International Holdings Limited (HKG:3933) Shares?

Dec 07

The United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?

Nov 23

Previsiones de crecimiento de beneficios e ingresos

SEHK:3933 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	16,393	3,206	N/A	3,756	7
12/31/2025	15,382	3,015	N/A	3,545	8
12/31/2024	14,664	2,928	N/A	3,545	8
6/30/2024	14,009	2,908	1,420	3,088	N/A
3/31/2024	13,875	2,805	1,267	2,763	N/A
12/31/2023	13,740	2,701	1,114	2,439	N/A
9/30/2023	13,399	2,469	1,376	2,504	N/A
6/30/2023	13,059	2,236	1,637	2,568	N/A
3/31/2023	12,197	1,909	1,444	2,300	N/A
12/31/2022	11,334	1,581	1,251	2,031	N/A
9/30/2022	10,750	1,288	1,066	1,683	N/A
6/30/2022	10,166	995	882	1,336	N/A
3/31/2022	9,935	991	968	1,439	N/A
12/31/2021	9,703	988	1,055	1,543	N/A
9/30/2021	9,445	1,056	1,047	1,647	N/A
6/30/2021	9,187	1,123	1,039	1,752	N/A
3/31/2021	8,980	913	1,035	1,660	N/A
12/31/2020	8,772	703	1,030	1,568	N/A
9/30/2020	8,690	626	1,128	1,625	N/A
6/30/2020	8,607	549	1,226	1,683	N/A
3/31/2020	8,500	595	1,293	1,742	N/A
12/31/2019	8,393	642	1,361	1,801	N/A
9/30/2019	8,100	765	1,147	1,618	N/A
6/30/2019	7,808	888	932	1,436	N/A
3/31/2019	7,659	785	806	1,324	N/A
12/31/2018	7,511	683	681	1,213	N/A
9/30/2018	7,395	373	640	1,104	N/A
6/30/2018	7,280	64	599	995	N/A
3/31/2018	7,053	73	N/A	883	N/A
12/31/2017	6,827	82	N/A	770	N/A
9/30/2017	6,640	-34	N/A	957	N/A
6/30/2017	6,454	-150	N/A	1,144	N/A
3/31/2017	6,266	-211	N/A	1,109	N/A
12/31/2016	6,078	-272	N/A	1,074	N/A
9/30/2016	6,083	-216	N/A	976	N/A
6/30/2016	6,076	-159	N/A	875	N/A
3/31/2016	6,195	-32	N/A	1,182	N/A
12/31/2015	6,446	92	N/A	1,516	N/A
9/30/2015	6,597	148	N/A	1,522	N/A
6/30/2015	6,711	201	N/A	1,521	N/A
3/31/2015	6,565	373	N/A	1,460	N/A
12/31/2014	6,422	545	N/A	1,400	N/A
9/30/2014	6,179	552	N/A	1,436	N/A
6/30/2014	6,101	574	N/A	1,511	N/A
3/31/2014	6,112	306	N/A	1,347	N/A
12/31/2013	5,972	38	N/A	1,155	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (3.9% al año) de 3933 es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (3.9% al año) de 3933 crezcan menos que el mercado Hong Kong (11.6% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 3933 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6.1% al año) de 3933 crezcan más despacio que el mercado de Hong Kong (7.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.1% al año) de 3933 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 3933 sea baja dentro de 3 años (19.5%).

United Laboratories International Holdings Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 18% to HK$10.66

Price target increased by 8.4% to HK$9.06

Price target increased by 12% to HK$8.36

Price target increased by 7.4% to HK$5.85

Price target increased to HK$5.42

Price target decreased to HK$5.02

Recent updates

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings: EPS exceeds analyst expectations

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified

The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement

United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt

With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case

New minor risk - Share price stability

Price target increased by 18% to HK$10.66

Price target increased by 8.4% to HK$9.06

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

Price target increased by 12% to HK$8.36

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

Is United Laboratories International Holdings (HKG:3933) A Risky Investment?

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.4% to HK$5.85

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to HK$5.42

United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Less than half of directors are independent

Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

Price target decreased to HK$5.02

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Price target decreased to HK$5.54

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to HK$6.38

Less than half of directors are independent

Investor sentiment improved over the past week

Price target decreased to HK$7.34

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

Investor sentiment deteriorated over the past week

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

Investor sentiment deteriorated over the past week

The United Laboratories International Holdings Limited Announces Updated Information of the Group's Products

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

Consensus forecasts updated

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

The United Laboratories International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?

The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It

The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Investor sentiment improved over the past week